Intellia Therapeutics Company Insiders

NTLA Stock  USD 14.30  0.50  3.62%   
Intellia Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Intellia Therapeutics suggests that vertually all insiders are panicking. Intellia Therapeutics employs about 526 people. The company is managed by 12 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 43.83 employees per reported executive.
Nessan Bermingham  CEO
President CEO, Founder, Director
Laura SeppLorenzino  President
Executive Vice President Chief Scientific Officer

Intellia Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-10-02Michael P DubeDisposed 2012 @ 19.01View
2024-07-01Eliana ClarkDisposed 405 @ 22.93View
2024-03-04James BastaDisposed 2297 @ 32.99View
2024-01-08Laura Sepp-LorenzinoDisposed 2275 @ 28.87View
2024-01-03John M LeonardDisposed 19223 @ 29.46View
Monitoring Intellia Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.

Intellia Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Intellia Therapeutics' future performance. Based on our forecasts, it is anticipated that Intellia will maintain a workforce of about 530 employees by December 2024.
 
Covid

Intellia Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2781) % which means that it has lost $0.2781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5223) %, meaning that it created substantial loss on money invested by shareholders. Intellia Therapeutics' management efficiency ratios could be used to measure how well Intellia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 317.8 M, whereas Total Assets are forecasted to decline to about 686.6 M.
As of November 25, 2024, Common Stock Shares Outstanding is expected to decline to about 50.5 M. The current year's Net Loss is expected to grow to about (405.4 M)

Intellia Therapeutics Workforce Comparison

Intellia Therapeutics is regarded third in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 9,444. Intellia Therapeutics holds roughly 526 in number of employees claiming about 6% of equities under Health Care industry.

Intellia Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intellia Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intellia Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Intellia Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
3.0
3
1
 180,344 
 405.00 
2024-06-01
7.0
14
2
 153,218 
 1,505 
2024-03-01
1.125
18
16
 779,634 
 71,027 
2023-06-01
5.6667
17
3
 99,922 
 10,000 
2023-03-01
1.3333
20
15
 643,512 
 40,070 
2022-03-01
2.875
23
8
 372,732 
 23,302 
2021-12-01
0.2105
4
19
 17,300 
 34,600 
2021-09-01
0.2838
21
74
 496,280 
 724,637 
2021-06-01
0.3971
27
68
 256,624 
 1,401,019 
2021-03-01
0.5435
25
46
 1,234,160 
 1,372,373 
2020-12-01
0.7045
31
44
 439,675 
 586,549 
2020-09-01
0.5
6
12
 45,000 
 76,845 
2020-06-01
1.6667
10
6
 339,000 
 41,230 
2018-06-01
0.8333
5
6
 99,500 
 64,272 
2018-03-01
1.0
5
5
 278,410 
 597,890 
2017-12-01
0.4545
5
11
 515,000 
 2,196,566 
2017-09-01
0.25
2
8
 76,000 
 2,397,692 
2017-03-01
1.6
8
5
 878,245 
 742,264 
2016-06-01
0.8222
37
45
 33,026,396 
 60,056,189 

Intellia Therapeutics Notable Stakeholders

An Intellia Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intellia Therapeutics often face trade-offs trying to please all of them. Intellia Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intellia Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Rodolphe MBAFounder BoardProfile
Nessan BerminghamPresident CEO, Founder, DirectorProfile
John MDCEO PresidentProfile
Laura SeppLorenzinoExecutive Vice President Chief Scientific OfficerProfile
JD EsqGeneral VPProfile
Jennifer DoudnaFounder BoardProfile
Rachel HaurwitzCoFounderProfile
Glenn CPACFO VPProfile
Derek HicksExecutive OfficerProfile
Andrew MayFounder BoardProfile
David MDExecutive OfficerProfile
Derrick RossiFounder BoardProfile

About Intellia Therapeutics Management Performance

The success or failure of an entity such as Intellia Therapeutics often depends on how effective the management is. Intellia Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intellia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intellia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.37)(0.39)
Return On Capital Employed(0.43)(0.46)
Return On Assets(0.37)(0.39)
Return On Equity(0.46)(0.48)
Please note, the presentation of Intellia Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellia Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Intellia Therapeutics' management manipulating its earnings.

Intellia Therapeutics Workforce Analysis

Traditionally, organizations such as Intellia Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intellia Therapeutics within its industry.

Intellia Therapeutics Manpower Efficiency

Return on Intellia Therapeutics Manpower

Revenue Per Employee69K
Revenue Per Executive3M
Net Loss Per Employee914.8K
Net Loss Per Executive40.1M
Working Capital Per Employee1.7M
Working Capital Per Executive73.6M

Complementary Tools for Intellia Stock analysis

When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments